• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Clear Street Launches Healthcare & Biotechnology Equity Research

    12/17/24 2:00:00 PM ET
    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $CGEM alert in real time by email

    Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises

    Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives products and markets.

    Ed Tilly, President and CEO-Elect of Clear Street said, "The launch of our Healthcare Equity Research franchise demonstrates our commitment to providing capabilities that align with our clients' evolving needs. Our expanded equity research service complements our full suite of existing products and allows us to continue providing institutional clients the tools, teams and capabilities they need to navigate global markets and execute successful investment strategies."

    Led by Director of Research Mara Goldstein, the new Healthcare Research franchise provides in-depth market analysis and investment insights to the firm's expanding institutional client base. To launch coverage, Clear Street has appointed Kaveri Pohlman, Ph.D. and William "Bill" Maughan, Ph.D. as Managing Directors and Senior Equity Analysts, reporting to Ms. Goldstein.

    "Fueled by scientific advancements across all fields of medicine, the healthcare sector, particularly biotechnology, has grown immensely and has become a fundamentally important sector of the economy for investors," said Ms. Goldstein. "As the number of biotechnology companies continues to grow, we think it's important to be a voice in the space, analyzing and highlighting under-followed and under-represented companies that our clients, such as specialist hedge funds and dedicated healthcare fund investors care about."

    Dr. Kaveri Pohlman's research coverage will initially focus on oncology and autoimmune disease (I&I), spanning multiple technologies, from cell to gene therapy. Prior to joining Clear Street, Dr. Pohlman was a Senior Analyst at BTIG where she covered large and small-cap biotechnology companies. Dr. Pohlman earned a Ph.D. in molecular and cellular biology from SUNY Downstate Medical Center, an MS in biotechnology from New York University's Tandon School of Engineering and an MBA from Birla Institute of Management Technology.

    Dr. Bill Maughan brings deep experience in Equity Research across several therapeutic areas, and will continue to do so at Clear Street, including oncology, ophthalmology and genetic medicine, including RNA technologies. Prior to joining Clear Street, Dr. Maughan was a Senior Biotechnology Analyst with Canaccord Genuity, focusing on solid tumor oncology. Dr. Maughan earned a Ph.D. in Biochemistry, Cell and Molecular Biology at the Weill Cornell Graduate School of Medical Sciences and a bachelor's degree in Biological Sciences from Fordham University.

    Specific coverage launch includes:

    Healthcare: Biotechnology

    • Cargo Therapeutics (NASDAQ:CRGX)
    • Century Therapeutics (NASDAQ:IPSC)
    • Cullinan Therapeutics (NASDAQ:CGEM)
    • Delcath Systems (NASDAQ:DCTH)
    • Enliven Therapeutics (NASDAQ:ELVN)
    • Erasca (NASDAQ:ERAS)
    • Immatics (NASDAQ:IMTX)
    • Janux Therapeutics (NASDAQ:JANX)
    • MoonLake Immunotherapeutics (NASDAQ:MLTX)
    • Nuvation Bio (NYSE:NUVB)
    • Protagonist Therapeutics (NASDAQ:PTGX)
    • YmAbs Therapeutics (NASDAQ:YMAB)

    The launch of Healthcare Equity Research enhances Clear Street's growing research franchise and complements the Company's already existing product offerings across prime brokerage, professional clearing, futures trading and investment banking services. The expanding Equity Research offering demonstrates Clear Street's commitment to areas where institutional clients are actively seeking specialized insights. The Company also recently launched Clear Street UK, a pivotal step in building a global, full-service institutional business powered by cloud-based, financial technology.

    About Clear Street:

    Clear Street is modernizing the brokerage ecosystem with financial technology and services that empower market participants with real-time data and best-in-class products, tools and teams, to navigate capital markets around the world. Complemented by white-glove service, Clear Street's cloud-native, proprietary product suite delivers financing, derivatives, execution and more to power client success, adding efficiency to the market and enabling clients to minimize risk, redundancy and cost. Clear Street's goal is to create a single platform for every asset class, in every country and in any currency. For more information, visit https://clearstreet.io.

    Clear Street does not provide investment, legal, regulatory, tax, or compliance advice. Consult professionals in these fields to address your specific circumstances. These materials are: (i) solely an overview of Clear Street's products and services; (ii) provided for informational purposes only; and (iii) subject to change without notice or obligation to replace any information contained therein.

    Products and services are offered by Clear Street LLC as a Broker Dealer member FINRA and SIPC and a Futures Commission Merchant registered with the CFTC and member of NFA. Additional information about Clear Street is available on FINRA BrokerCheck, including its Customer Relationship Summary and NFA BASIC | NFA (futures.org).

    Copyright © 2024 Clear Street LLC. All rights reserved. Clear Street and the Shield Logo are Registered Trademarks of Clear Street LLC

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241217931998/en/

    Get the next $CGEM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGEM
    $CRGX
    $DCTH
    $ELVN

    CompanyDatePrice TargetRatingAnalyst
    Nuvation Bio Inc.
    $NUVB
    9/30/2025$10.00Buy
    Jefferies
    MoonLake Immunotherapeutics
    $MLTX
    9/30/2025$2.00Outperform → Underperform
    Wolfe Research
    MoonLake Immunotherapeutics
    $MLTX
    9/30/2025$5.00Buy → Neutral
    Citigroup
    MoonLake Immunotherapeutics
    $MLTX
    9/29/2025$8.00Buy → Hold
    Jefferies
    MoonLake Immunotherapeutics
    $MLTX
    9/29/2025Buy → Neutral
    BTIG Research
    MoonLake Immunotherapeutics
    $MLTX
    9/29/2025$10.00Outperform → Sector Perform
    RBC Capital Mkts
    MoonLake Immunotherapeutics
    $MLTX
    9/29/2025$13.00Buy → Hold
    Stifel
    Immatics N.V.
    $IMTX
    9/18/2025$16.00Buy
    Guggenheim
    More analyst ratings

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Nuvation Bio with a new price target

    Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00

    9/30/25 8:57:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Underperform and set a new price target of $2.00

    9/30/25 8:33:10 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Citigroup with a new price target

    Citigroup downgraded MoonLake Immunotherapeutics from Buy to Neutral and set a new price target of $5.00

    9/30/25 8:32:59 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

    Trial initiation follows the recent approval of IBTROZI™ (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 study evaluating the efficacy and safety of IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of patients with resected ROS1-positive (ROS1+) early-stage non-small cell lung cancer (NSCLC). "While surgical resection is a standard treatment for early-stage non-small cell lung c

    9/30/25 7:30:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

    VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the robustness of the results: difference between the two methods relates to the statistical handling of intercurrent eventsIn the combined VELA program, patients treated with sonelokimab experienced a clinically

    9/28/25 12:04:41 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology, will present data evaluating the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath's CHEMOSAT® Hepatic Delivery System for percutaneous hepatic perfusion with melphalan in patients with metastati

    9/22/25 4:01:00 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    SEC Filings

    View All

    SEC Form 144 filed by Enliven Therapeutics Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    9/29/25 5:19:09 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

    9/29/25 7:15:53 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.

    15-12G - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)

    9/26/25 8:30:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $81,005 worth of shares (4,000 units at $20.25) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    9/30/25 5:53:12 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Kintz Samuel sold $74,228 worth of shares (3,700 units at $20.06) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    9/30/25 5:51:49 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $30,045 worth of shares (1,500 units at $20.03) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    9/25/25 7:44:47 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:21 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:19 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Leadership Updates

    Live Leadership Updates

    View All

    Immatics Announces Second Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase 1b trial presented at the 2025 ASCO Annual Meeting: 56% cORR, 12.1 months mDOR at 13.4 months mFU, 6.1 months mPFS and 15.9 months mOS Anzu-cel (IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data

    8/13/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

    PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

    7/24/25 4:05:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

    7/17/25 4:30:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Financials

    Live finance-specific insights

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

    Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval National Comprehensive Cancer Network® added taletrectinib (IBTROZI) as a Preferred Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $607.7 million as of June 30, 2025 Company to host a conference call today at 8:00 a.m. ET Nuvation Bio Inc. (

    8/7/25 7:30:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Century Therapeutics Inc.

    SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    11/27/24 6:51:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care